Price
$0.03
Increased by +29.62%
Dollar volume (20D)
4.19 K
ADR%
37.65
Shares float
9.78 M
Shares short
122.01 K [1.25%]
Shares outstanding
0.00
Market cap
N/A
Beta
-0.86
Price/earnings
N/A
20D range
0.01 0.05
50D range
0.01 0.05
200D range
0.01 0.05

SeaStar Medical Holding Corporation, a commercial-stage medical device company, develops a proprietary platform therapy to reduce the consequences of hyperinflammation on vital organs in the United States.

The company offers the selective cytopheretic device (SCD), which is a disease-modifying device that neutralizes over-active immune cells and stops the cytokine storm that yields destructive hyperinflammation; and QUELIMMUNE, an SCD therapy for pediatric patients with acute kidney injury (AKI) due to sepsis.

It also develops NEUTRALIZE-AKI, an SCD therapy that is in clinical trials for adult patients with AKI; and other products in various therapeutic areas, including cardiorenal syndrome, hepatorenal syndrome, and myocardial stunning in end-stage renal disease.

SeaStar Medical Holding Corporation was founded in 2007 and is headquartered in Denver, Colorado.

  • Quarterly earnings
  • Annual earnings
Reported date EPSChange YoY EstimateSurprise
  • Quarterly financials
  • Annual financials
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Sep 30, 23 0.00
Decreased by N/A%
-7.43 M
Decreased by -292.49%
Decreased by N/A%
Decreased by N/A%
Jun 30, 23 0.00
Decreased by N/A%
-3.67 M
Decreased by -306.76%
Decreased by N/A%
Decreased by N/A%
Mar 31, 23 0.00
Decreased by N/A%
-5.26 M
Decreased by -424.10%
Decreased by N/A%
Decreased by N/A%
Dec 31, 22 0.00
Decreased by N/A%
-19.21 M
Decreased by -1.64 K%
Decreased by N/A%
-
Sep 30, 22 0.00
Decreased by N/A%
-1.89 M
Decreased by -77.65%
Decreased by N/A%
-
Jun 30, 22 0.00 - -902.00 K -
Decreased by N/A%
-
Mar 31, 22 0.00 - -1.00 M -
Decreased by N/A%
-
Jun 30, 21 N/A - -1.11 M - - -
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY